A record of what Private Bank Trader Analysis said publicly, with the source. Not advice.
“Maintained "Buy" rating on Biocon, raising the target price to Rs 435 from Rs 400, implying a potential upside of 20% from Rs 360. This is driven by recent USFDA clearance of its Malaysia and Bengaluru facilities, expected to boost confidence in its biosimilar launch pipeline. Annualized revenue is projected to grow from $1 billion in H1FY25 to $1.2 billion in FY26, with focus on deleveraging and new product performance.”
Private Bank Trader Analysis’s track record (trackable calls only): 16 graded calls · 95% CI 57–93%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹435, as stated.
Window: 12 months, the default when no time frame is stated.
Neither the target ₹435 was reached on a close by the end of the window. Miss.
The grader’s working: R4 TARGET_CALL: entered ₹387.65 on 2025-01-14 (next trading session's close); neither target nor stop reached by window end 2026-01-13. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.